Cargando…

MCL-1 dependency as a novel vulnerability for aggressive B cell lymphomas

Detalles Bibliográficos
Autores principales:	Wang, Michelle Y., Li, Tao, Ren, Yuan, Shah, Bijal D., Lwin, Tint, Gao, Jing, Shain, Kenneth H., Zhang, Wei, Zhao, Xiaohong, Tao, Jianguo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809345/ https://www.ncbi.nlm.nih.gov/pubmed/33446629 http://dx.doi.org/10.1038/s41408-020-00402-2

Ejemplares similares

Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas
por: Gao, Jing, et al.
Publicado: (2021)

Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma
por: Zhao, Xiaohong, et al.
Publicado: (2021)

Purported Mcl-1 inhibitor marinopyrrole A fails to show selective cytotoxicity for Mcl-1-dependent cell lines
por: Eichhorn, J M, et al.
Publicado: (2013)

Epigenetics, c-Myc and Aggressive B-cell Lymphomas
por: Zhang, Yizhuo, et al.
Publicado: (2012)

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma
por: Zhao, Xiaohong, et al.
Publicado: (2017)

Male sterility in Mcl-1-flox mice is not due to enhanced Mcl1 protein stability
por: Ah-Cann, Casey, et al.
Publicado: (2016)

A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia
por: Zeidner, Joshua F., et al.
Publicado: (2021)

Anti-Ma2 Paraneoplastic Encephalitis Associated with Ileal Lymphoma
por: Guan, Hong-Zhi, et al.
Publicado: (2015)

Targeted genomic analysis of cutaneous T cell lymphomas identifies a subset with aggressive clinicopathological features
por: Argyropoulos, Kimon V., et al.
Publicado: (2020)

P1110: REAL-WORLD TREATMENT PATTERNS OF BRUTON TYROSINE KINASE INHIBITORS (BTKI) IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) IN COMMUNITY ONCOLOGY PRACTICES IN THE UNITED STATES (US)
por: Shah, Bijal, et al.
Publicado: (2023)

Mcl-1 levels need not be lowered for cells to be sensitized for ABT-263/737-induced apoptosis
por: Yamaguchi, R, et al.
Publicado: (2011)

Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT
por: Breen, William G., et al.
Publicado: (2022)

MCL-1 is a clinically targetable vulnerability in breast cancer
por: Winder, Matthew L, et al.
Publicado: (2022)

Molecular characteristics of diffuse large B-cell lymphoma in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin lymphomas (PETAL) trial: correlation with interim PET and outcome
por: Richter, Julia, et al.
Publicado: (2019)

MYC break-apart FISH probe set reveals frequent unbalanced patterns of uncertain significance when evaluating aggressive B-cell lymphoma
por: Gagnon, Marie-France, et al.
Publicado: (2021)

Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma
por: Prutsch, Nicole, et al.
Publicado: (2018)

Single-nucleotide variants in TGFB1, TGFBR2, IL17A, and IL17F immune response genes contribute to follicular lymphoma susceptibility and aggressiveness
por: Assis-Mendonça, Guilherme Rossi, et al.
Publicado: (2020)

Letter to the Editor: Supporting the Sick and the Vulnerable
por: del Castillo, Fides A.
Publicado: (2023)

Author Response: Supporting the Sick and the Vulnerable
por: Camellia, Artha, et al.
Publicado: (2023)

Public health systems strengthening in Africa: The role of South Africa Field Epidemiology and Laboratory Training Programme
por: Kuonza, Lazarus, et al.
Publicado: (2011)

Nuances in the Management of Aggressive Lymphomas
por: Hamlin, Paul A., et al.
Publicado: (2017)

Correction: Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma
por: Prutsch, Nicole, et al.
Publicado: (2020)

COVID-19 and selective vulnerability to Parkinson's disease
por: Pavel, Alexandra, et al.
Publicado: (2020)

Demographic Evidence of Sex Differences in Vulnerability to Infectious Diseases
por: Garenne, Michel
Publicado: (2015)

Neuroticism as a Marker of Vulnerability to COVID-19 Infection
por: Khosravi, Mohsen
Publicado: (2020)

MCL-1ES Induces MCL-1L-Dependent BAX- and BAK-Independent Mitochondrial Apoptosis
por: Kim, Jae-Hong, et al.
Publicado: (2013)

CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo
por: Gregory, G P, et al.
Publicado: (2015)

Do All Children With Autoimmune Encephalitis Need Aggressive Immunotherapy?
por: Kamate, Mahesh, et al.
Publicado: (2020)

Aggressive Angiomyxoma with Lymphangitis a Rare Entity – Case Report
por: Patrick, Safa, et al.
Publicado: (2021)

Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019)

MicroRNA-448 suppresses the proliferation, migration, and invasion of glioma cell line U251 by targeting B-cell lymphoma-2
por: Zhou, Peng, et al.
Publicado: (2020)

Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes
por: Tang, Y-T, et al.
Publicado: (2017)

Venerable but Vulnerable: When Centenarians Encounter Coronavirus Disease 2019
por: Dessemon, Juliette, et al.
Publicado: (2022)

Letter to the Editor: Insights on Health, Religion/Spirituality, and Vulnerable Populations
por: del Castillo, Fides A.
Publicado: (2023)

The MCL-1 BH3 Helix is an Exclusive MCL-1 inhibitor and Apoptosis Sensitizer
por: Stewart, Michelle L., et al.
Publicado: (2010)

An 11 years delayed diagnosis of primary pulmonary diffuse large B cell lymphoma
por: Yu, Jin-Yan, et al.
Publicado: (2019)

Inhibition of MCL1 induces apoptosis in anaplastic large cell lymphoma and in primary effusion lymphoma
por: Quentmeier, Hilmar, et al.
Publicado: (2022)

The need to address the impact of COVID-19 on TB control for vulnerable groups
por: Aranda, Z., et al.
Publicado: (2022)

A case report of primary adrenal lymphoma: A rare but aggressive and invasive disease
por: Yang, Yunyun, et al.
Publicado: (2020)

Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3
por: Eskelund, Christian Winther, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qibgdquqe04cn94hnuf9fdkmeg